SP1/ADAM10/DRP1 Axis Regulates SMC–EC Crosstalk in Hypoxic PH

Study Background and Research Question

Hypoxia pulmonary hypertension (HPH) is a severe vascular complication most commonly arising from chronic obstructive pulmonary disease (COPD) and interstitial lung disorders, including idiopathic pulmonary fibrosis (IPF) and combined pulmonary fibrosis and emphysema (CPFE). The condition is characterized by elevated mean pulmonary artery pressure (mPAP ≥ 25 mmHg) and leads to right heart failure, with a three-year survival rate of approximately 68–70% in advanced cases (source: paper). Despite the high mortality and morbidity, current therapeutic interventions offer only limited efficacy. A critical factor in HPH progression is the pathological remodeling of the pulmonary artery, driven by aberrant proliferation and suppressed apoptosis of both endothelial cells (ECs) and smooth muscle cells (SMCs). The molecular cues governing intercellular communication between these cell types under hypoxic stress are still being elucidated. Li et al. sought to clarify whether a specific molecular axis—SP1/ADAM10/DRP1—mediates the maladaptive crosstalk between ECs and SMCs during hypoxic injury.

Key Innovation from the Reference Study

The central innovation of this study lies in the discovery that the transcription factor SP1 upregulates ADAM10 expression in hypoxic endothelial cells. The secreted ADAM10, in turn, acts in a paracrine fashion to alter the fate of neighboring SMCs by activating DRP1-dependent mitochondrial dynamics and the PI3K/AKT/mTOR signaling cascade. This molecular relay not only promotes SMC proliferation but also suppresses apoptosis, thereby facilitating the vascular remodeling characteristic of HPH (source: paper). Previous research has highlighted the role of extracellular vesicle-mediated signaling, microRNAs, and growth factors in EC–SMC communication. However, this work uniquely positions the SP1/ADAM10/DRP1 axis as a central mediator of hypoxia-induced pro-proliferative and anti-apoptotic phenotypes in pulmonary vascular SMCs.

Methods and Experimental Design Insights

Li et al. combined in vivo and in vitro experiments to dissect the mechanisms underlying EC–SMC crosstalk during hypoxia:

• Expression analysis of ADAM10 in lung tissues and ECs from hypoxia-treated rats.
• Application of siRNA-mediated knockdown and overexpression strategies for ADAM10 in ECs.
• Conditioned medium transfer assays: Media from hypoxic EC cultures, with or without ADAM10 manipulation, was used to treat SMC cultures.
• Assessment of SMC proliferation (EdU incorporation, cell counting) and apoptosis (apoptosis assay, annexin V staining).
• Evaluation of signaling pathway activation (Western blot for DRP1, PI3K, AKT, mTOR).
• Pharmacological interventions: SMCs exposed to EC-derived conditioned media were co-treated with Mdivi-1 (selective DRP1 inhibitor) or LY294002 (PI3K inhibitor) to dissect pathway dependencies.
• Bioinformatic promoter analysis (JASPAR) and siRNA validation to establish SP1 as a transcriptional regulator of ADAM10.

This integrated strategy enabled the authors to link molecular, cellular, and functional outcomes in both animal and cell culture models of HPH.

Core Findings and Why They Matter

Key findings from the study are as follows:

• ADAM10 is upregulated in hypoxic pulmonary ECs and rat lung tissue. Knockdown of ADAM10 alleviated HPH severity and reversed the malignant phenotype of hypoxic ECs (source: paper).
• Conditioned medium from hypoxic ECs with high ADAM10 content promoted SMC proliferation and reduced apoptosis. This effect was diminished when ADAM10 was knocked down in ECs.
• SMCs exposed to ADAM10-rich conditioned medium displayed increased expression of DRP1, PI3K, AKT, and mTOR. Conversely, knockdown of ADAM10 in ECs suppressed these signals in SMCs.
• Pharmacological inhibition of DRP1 (using Mdivi-1) or PI3K (using LY294002) reversed the pro-proliferative, anti-apoptotic effects of ADAM10 overexpression. This confirms that ADAM10 acts via DRP1 and PI3K/AKT/mTOR signaling to modulate SMC fate.
• SP1 transcriptionally regulates ADAM10 expression in ECs under hypoxic stress. Downregulation of SP1 led to reduced ADAM10 levels.

These results collectively define a paracrine molecular circuit—SP1/ADAM10/DRP1—linking hypoxic EC activation to SMC-driven vascular remodeling. This mechanistic insight expands the understanding of mitochondrial dynamics research, particularly the intersection of mitochondrial fission, apoptosis, and intercellular signaling in pulmonary vascular disease.

Comparison with Existing Internal Articles

Recent internal reviews have established Mdivi-1 as a foundational tool in mitochondrial dynamics and apoptosis pathway studies:

• Mdivi-1 as a Selective DRP1 Inhibitor: Redefining Mitochondrial Dynamics explores emerging evidence for Mdivi-1 in intercellular signaling and disease models, including pulmonary hypertension, emphasizing its utility in dissecting DRP1-dependent mitochondrial outer membrane permeabilization and apoptosis mechanisms.
• Strategic Disruption of Mitochondrial Fission: Mdivi-1 provides a mechanistic blueprint for using Mdivi-1 in translational models, noting its relevance in neuroprotection and vascular pathology studies. The present study by Li et al. offers direct empirical support for these review perspectives, specifically illustrating the value of pharmacological DRP1 inhibition in modulating SMC fate in HPH models.
• For atomic-level benchmarks and workflow protocols, Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission Studies can be consulted, complementing the experimental approach used by Li et al. in pulmonary vascular cell systems.

Thus, Li et al. provide a primary experimental demonstration of concepts outlined in these internal resources, strengthening the case for targeting mitochondrial fission in vascular remodeling contexts.

Limitations and Transferability

While the study robustly establishes the SP1/ADAM10/DRP1 axis in hypoxic pulmonary hypertension models, several limitations warrant mention:

• The in vivo work is performed in rat models, which may not fully recapitulate the heterogeneity of human disease. Translational studies in human tissues or organoids are needed.
• Off-target effects of pharmacological inhibitors (including Mdivi-1 and LY294002) are possible; genetic models (e.g., conditional Drp1 knockout) would further substantiate these findings.
• The broader impact of ADAM10 on other vascular cell types and the role of additional paracrine mediators remain to be explored.

Nevertheless, the experimental workflow and molecular targets identified are likely to be applicable to related models of vascular remodeling and mitochondrial dysfunction, including neuroprotection in ischemic retina, where DRP1-dependent fission and apoptosis play critical roles (source: internal article).

Protocol Parameters

• apoptosis assay | 50 μM Mdivi-1 | cell-based (SMCs, ECs) | Selective DRP1 inhibition to assess mitochondrial outer membrane permeabilization and apoptosis | product_spec
• mitochondrial dynamics research | 50 μM Mdivi-1 | in vitro mitochondrial fission assay | Quantifies DRP1-dependent mitochondrial fragmentation | workflow_recommendation
• in vivo SMC phenotype modulation | 50 mg/kg Mdivi-1 (i.p.) | rat models of HPH | Tests DRP1 role in vascular remodeling | product_spec
• neuroprotection in ischemic retina | 50 mg/kg Mdivi-1 (i.p.) | mouse/rat retina models | Evaluates DRP1/mitochondrial fission in retinal ganglion cell survival | internal_article

Research Support Resources

For researchers aiming to replicate or extend these findings, Mdivi-1 (SKU A4472) is available as a highly selective, cell-permeable inhibitor of DRP1. It is suitable for both cell-based and animal model applications in mitochondrial fission and apoptosis assays. For detailed handling and workflow integration, consult product documentation and recent best-practice reviews. APExBIO provides high-quality reagents aligned with protocols used in this and related mitochondrial dynamics research.